Guangxi LiuYao Group Co., Ltd. Class A

Guangxi LiuYao Group Co., Ltd. Class A

SSSE:603368
16.77
CNY
-0.57
(-3.29%)
1.61EPS
9.56P/E
6.03BMarket Cap
Mar 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
19.83
24.18
22.67
28.11
26.06
32.32
40.97
43.15
47.41
52.69
57.57
54.76
52.8
54.57
Basic EPS, GAAP
0.65
0.73
0.73
1.19
1.11
1.46
1.89
1.96
1.56
1.94
2.35
2.21
1.79
1.59
Free Cash Flow per Basic Share
-0.23
-1.09
-0.84
-0.07
-1.44
-0.69
0.45
1.11
0.19
0.89
1.17
1.79
2.25
- -
Dividend per Share
0.24
0.4
0.25
0.36
0.33
0.64
0.76
0.87
0.96
0.96
0.98
1.07
1.13
1.18
Book Value per Share
2.18
4.03
4.64
8.8
9.63
10.6
12.06
14.06
15.07
16.48
18.27
19.11
19.71
20.31
Tangible Book Value per Share
1.9
3.8
4.34
8.51
9.35
8.1
9.4
11.37
12.33
13.66
15.49
16.63
17.28
17.85
Basic Weighted Avg Shares
229
234
287
269
363
362
363
363
361
362
362
387
396
391
Sales/Revenue/Turnover
4,548
5,655
6,508
7,559
9,447
11,715
14,857
15,669
17,135
19,053
20,812
21,182
20,926
21,312
Operating Margin (%)
4.92
4.94
4.74
5.31
5.57
6.14
6.99
6.92
5.79
6.05
6.48
5.99
5.49
4.78
Depreciation Expense
4
6
9
13
25
38
53
71
170
203
202
206
199
- -
Net Income, GAAP
149
170
208
321
401
528
685
712
564
702
850
855
709
620
Effective Tax Rate (%)
18.82
17.64
15.6
15.3
15.22
14.5
15.45
14.8
15.05
14.76
13.11
13.52
17.17
18.38
Profit Margin (%)
3.29
3
3.2
4.25
4.25
4.51
4.61
4.54
3.29
3.68
4.08
4.04
3.39
2.91
Working Capital
378
1,027
1,012
2,716
2,860
2,794
3,222
4,509
4,759
5,297
5,703
6,755
6,206
6,729
LT Debt
- -
75
- -
- -
- -
430
364
1,116
1,134
1,107
1,140
1,132
642
1,134
Total Equity
501
1,174
1,361
3,238
3,569
4,047
4,658
5,445
5,806
6,365
7,064
7,937
8,142
8,372
Return on Invested Capital (%)
15.51
12.3
11.41
12.18
11.12
11.37
11.89
9.45
6.71
7.5
8.27
7.44
6.03
- -
Return on Capital (%)
19.02
14.12
11.43
10.99
10.18
10.86
11.52
10.05
6.95
8.57
9.37
8.95
7.16
- -
Return on Common Equity (%)
33.97
20.5
16.77
14.21
12.01
14.4
16.68
15.03
10.68
12.28
13.5
12
9.18
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3,466
3,289
2,747
LT Borrowings
882
945
1,032
LT Finance Leases
110
110
102
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
397
397
397
Market Capitalization
6,749
5,827
6,030

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
17,889
17,658
17,647
Cash, Cash Equivalents & STI
2,212
3,422
2,990
Accounts Receivable, Net
11,156
9,981
10,545
Inventories
3,395
3,164
3,260
Total Current Liabilities
11,177
11,026
10,918
Payables & Accruals
- -
- -
- -
ST Debt
3,466
3,289
2,747
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.58%
8.44%
2.58%
Free Cash Flow
290.35%
82.02%
29.32%
Net Income, GAAP
15.27%
1.67%
-17.01%
Sales/Revenue/Turnover
12.78%
6.07%
-1.21%
Total Cash Common Dividend
22.26%
7.56%
9.01%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,775
4,867
5,351
5,189
21,182
2025
5,317
4,984
- -
5,168
20,926
2026
5,377
5,149
5,618
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.83
0.41
0.63
0.35
2.21
2025
0.7
0.38
- -
0.16
1.79
2026
0.57
0.37
0.48
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.73
0.1
0.07
1.07
2025
0.13
0.85
- -
0.06
1.13
2026
1.52
-0.51
0.09
- -
- -

Company Description

CEO
Chaoyang Zhu
Full Time Employees
5,627
Sector
Distribution services
Industry
Medical distributors
Address
No. 68, Guantang Avenue Liuzhou GG China 545000
IPO Date
Dec 4, 2014
Website
lzyy.cn
Business
Guangxi LiuYao Group Co., Ltd, headquartered in Liuzhou, China, is a comprehensive pharmaceutical company primarily engaged in pharmaceutical wholesale, retail, and manufacturing industries. Founded in 1953 as Liuzhou Pharmaceutical Wholesale Station and restructured into a private enterprise in 2002, it is listed on the Shanghai Stock Exchange (Ticker: 603368.SS). The company offers a broad portfolio of products including various pharmaceuticals, traditional Chinese medicine pieces, traditional Chinese medicine formula granules, medical devices, consumables, and test reagents. It operates a wide-reaching distribution network supplying medical and health institutions, pharmaceutical distribution enterprises, and chain pharmacies, while also serving individual consumers through retail pharmacies. Additional business segments include supply chain value-added services, pharmaceutical Internet services, and terminal health services. Guangxi LiuYao Group serves markets primarily across China and has established a significant presence within its regional pharmaceutical industry. In recent years, the company has implemented strategic initiatives such as stock repurchases and an employee stock ownership plan aimed at enhancing shareholder value and incentivizing personnel. In 2025, Guangxi LiuYao Group launched a stock option incentive program granting 2.872 million stock options to eligible recipients, representing approximately 0.72% of its total share capital, reflecting a focus on talent retention and corporate governance. The company also engaged in active share repurchases, totaling over 5 million shares with a spending of around RMB 93.55 million, signaling confidence in its business outlook. Additionally, Guangxi LiuYao Group has explored collaborations, including high-level exchanges with industry leaders like Huawei to advance pharmaceutical intelligence capabilities, underscoring a commitment to innovation and digital transformation within the pharmaceutical sector. Overall, Guangxi LiuYao Group stands as a significant player in China's pharmaceutical distribution and manufacturing industries, combining traditional medicine production with modern healthcare product distribution and emerging digital health services, supported by recent strategic financial and operational initiatives to drive sustainable growth and competitiveness in the evolving healthcare market landscape.